FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023871410> ?p ?o ?g. }

• W2023871410 endingPage "399" @default.
• W2023871410 startingPage "393" @default.
• W2023871410 abstract "Gefitinib (Iressa®) is an orally active, selective EGFR tyrosine kinase inhibitor that blocks signal transduction pathways. Skin toxicity has been reported to be the major toxicity observed in patients treated with the EGFR-targeted tyrosine kinase inhibitors, such as gefitinib and erlotinib. Although the mechanisms underlying the development of the skin toxicity remain to be precisely clarified, immunological mechanisms are considered to be involved. We examined the correlations between the plasma levels of several cytokines and the risk of development of adverse events, especially skin toxicity, induced by the administration of gefitinib as first-line monotherapy in non-small cell lung cancer (NSCLC) patients. Paired plasma samples were obtained from a total 28 patients of non-small cell lung cancer; the first before the initiation of gefitinib administration (250 mg/day) (24 patients) and the second 2 or 4 weeks after the initiation of treatment (23 patients). The plasma concentrations of 17 major cytokines were measured using a bead-based multiplex assay. The median concentrations of eight of these cytokines before the start of treatment ranged from 0.06 (IL-5) to 58.26 (MIP-1β) (μg/ml). The concentrations of the remaining nine cytokines were under the detectable limit (<0.01 μg/ml) in more than 50% of the samples. Comparisons of the levels before and after treatment showed no significant differences for any of the cytokines measured. The MIP-1β levels were significantly lower in the patients with skin toxicity (16/24) as compared with those in the patients not showing any skin toxicity (59.1 ± 10.5 versus 119.0 ± 36.8; p = 0.042 by the two-sample t-test). The K-Nearest Neighbor Prediction (K = 3) showed the classification rate to be 75% for the prediction sets containing MIP-1β, IL-4 and IL-8. There were no significant associations between the levels of any of the cytokines measured and any other parameters, including the tumor response to the drug. In conclusion, the plasma MIP-1β level may be a useful predictor of the development of skin toxicity in patients receiving gefitinib treatment." @default.
• W2023871410 created "2016-06-24" @default.
• W2023871410 creator A5004282323 @default.
• W2023871410 creator A5018690593 @default.
• W2023871410 creator A5044307134 @default.
• W2023871410 creator A5050855780 @default.
• W2023871410 creator A5077306744 @default.
• W2023871410 date "2005-12-01" @default.
• W2023871410 modified "2023-10-17" @default.
• W2023871410 title "Plasma MIP-1β levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib" @default.
• W2023871410 cites W1541367222 @default.
• W2023871410 cites W1788753937 @default.
• W2023871410 cites W1968975905 @default.
• W2023871410 cites W1970708612 @default.
• W2023871410 cites W1973060721 @default.
• W2023871410 cites W1981071660 @default.
• W2023871410 cites W1991185441 @default.
• W2023871410 cites W2000221369 @default.
• W2023871410 cites W2013844343 @default.
• W2023871410 cites W2031162487 @default.
• W2023871410 cites W2037521712 @default.
• W2023871410 cites W2044507477 @default.
• W2023871410 cites W2047018108 @default.
• W2023871410 cites W2049399926 @default.
• W2023871410 cites W2049484790 @default.
• W2023871410 cites W2058992264 @default.
• W2023871410 cites W2064047613 @default.
• W2023871410 cites W2064326390 @default.
• W2023871410 cites W2074888333 @default.
• W2023871410 cites W2083272027 @default.
• W2023871410 cites W2087324107 @default.
• W2023871410 cites W2087455826 @default.
• W2023871410 cites W2103134643 @default.
• W2023871410 cites W2118555507 @default.
• W2023871410 cites W2120718661 @default.
• W2023871410 cites W2135148499 @default.
• W2023871410 cites W2139248078 @default.
• W2023871410 cites W2146404049 @default.
• W2023871410 cites W2157036179 @default.
• W2023871410 cites W2160483166 @default.
• W2023871410 cites W2168377135 @default.
• W2023871410 cites W4240355703 @default.
• W2023871410 doi "https://doi.org/10.1016/j.lungcan.2005.07.012" @default.
• W2023871410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16153743" @default.
• W2023871410 hasPublicationYear "2005" @default.
• W2023871410 type Work @default.
• W2023871410 sameAs 2023871410 @default.
• W2023871410 citedByCount "17" @default.
• W2023871410 countsByYear W20238714102013 @default.
• W2023871410 countsByYear W20238714102016 @default.
• W2023871410 countsByYear W20238714102019 @default.
• W2023871410 countsByYear W20238714102020 @default.
• W2023871410 countsByYear W20238714102021 @default.
• W2023871410 countsByYear W20238714102022 @default.
• W2023871410 crossrefType "journal-article" @default.
• W2023871410 hasAuthorship W2023871410A5004282323 @default.
• W2023871410 hasAuthorship W2023871410A5018690593 @default.
• W2023871410 hasAuthorship W2023871410A5044307134 @default.
• W2023871410 hasAuthorship W2023871410A5050855780 @default.
• W2023871410 hasAuthorship W2023871410A5077306744 @default.
• W2023871410 hasConcept C121608353 @default.
• W2023871410 hasConcept C126322002 @default.
• W2023871410 hasConcept C170493617 @default.
• W2023871410 hasConcept C2776256026 @default.
• W2023871410 hasConcept C2778087573 @default.
• W2023871410 hasConcept C2778820342 @default.
• W2023871410 hasConcept C2779438470 @default.
• W2023871410 hasConcept C2780580887 @default.
• W2023871410 hasConcept C2781047374 @default.
• W2023871410 hasConcept C29730261 @default.
• W2023871410 hasConcept C42362537 @default.
• W2023871410 hasConcept C71924100 @default.
• W2023871410 hasConcept C98274493 @default.
• W2023871410 hasConceptScore W2023871410C121608353 @default.
• W2023871410 hasConceptScore W2023871410C126322002 @default.
• W2023871410 hasConceptScore W2023871410C170493617 @default.
• W2023871410 hasConceptScore W2023871410C2776256026 @default.
• W2023871410 hasConceptScore W2023871410C2778087573 @default.
• W2023871410 hasConceptScore W2023871410C2778820342 @default.
• W2023871410 hasConceptScore W2023871410C2779438470 @default.
• W2023871410 hasConceptScore W2023871410C2780580887 @default.
• W2023871410 hasConceptScore W2023871410C2781047374 @default.
• W2023871410 hasConceptScore W2023871410C29730261 @default.
• W2023871410 hasConceptScore W2023871410C42362537 @default.
• W2023871410 hasConceptScore W2023871410C71924100 @default.
• W2023871410 hasConceptScore W2023871410C98274493 @default.
• W2023871410 hasIssue "3" @default.
• W2023871410 hasLocation W20238714101 @default.
• W2023871410 hasLocation W20238714102 @default.
• W2023871410 hasOpenAccess W2023871410 @default.
• W2023871410 hasPrimaryLocation W20238714101 @default.
• W2023871410 hasRelatedWork W2015104488 @default.
• W2023871410 hasRelatedWork W2088932689 @default.
• W2023871410 hasRelatedWork W2168841302 @default.
• W2023871410 hasRelatedWork W2184487997 @default.
• W2023871410 hasRelatedWork W2254126652 @default.
• W2023871410 hasRelatedWork W2280113021 @default.
• W2023871410 hasRelatedWork W2348666640 @default.

• next